Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Oncology · Chronic Lymphocytic Leukemia

Active Monitoring and Symptoms

At a Glance

During the CLL 'watch and wait' phase, your doctor actively monitors your blood work and symptoms every 3 to 6 months. Treatment is triggered by specific signs like extreme fatigue, drenching night sweats, rapidly swelling lymph nodes, or declining red blood cell and platelet counts.

The period of Watch and Wait is not a passive time; it is a period of active monitoring designed to ensure you only start treatment when the benefits outweigh the risks [1][2]. During this phase, you are a partner with your medical team, helping them track how the CLL is behaving in your unique body.

What Active Monitoring Looks Like

For most patients, active monitoring involves a physical exam and blood work every 3 to 6 months [3][4]. Your doctor is looking for two main things: changes in how you feel and changes in your blood counts.

How Will I Know It Is Time to Treat?

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) has established specific “triggers” for ending surveillance and starting treatment [5]. You do not need to have all of these; any one of them can be a signal that the disease is becoming active [5][1].

1. The “B Symptoms” (Constitutional Symptoms)

These are signs that the cancer is affecting your whole body’s metabolism [6].

  • Unexplained Weight Loss: Losing more than 10% of your body weight in a 6-month period without dieting [5][6].
  • Drenching Night Sweats: These are not just “hot flashes.” They are sweats so intense you must change your clothes or bed linens, occurring for more than a month [5][7].
  • Severe Fatigue: This is defined as exhaustion so profound that it prevents you from working or performing your usual daily activities [5][6].
  • Persistent Fever: A temperature above 100.4°F (38°C) for at least 2 weeks that isn’t caused by an infection [5].

CRITICAL SAFETY NOTE ON FEVERS: Because your immune system is compromised by the CLL, you cannot wait two weeks to see if a fever is a “B-symptom.” Any fever over 100.4°F must be reported to your medical team immediately. Infections are the biggest risk in CLL, and a fever is an infection until your doctor proves otherwise.

2. Physical Signs: Lumps and Organs

CLL cells often cluster in the lymph nodes or the spleen [8].

  • Lymphadenopathy: This is the medical term for swollen lymph nodes. Treatment is often considered if nodes become “massive” (larger than 10 cm) or are growing very quickly [5][2].
  • Splenomegaly: An enlarged spleen. You might feel “full” quickly when eating or feel a dull ache on your left side. A spleen that extends more than 6 cm below the ribs is a clinical trigger for treatment [5].

3. Laboratory Signs: The Numbers

Your blood work provides the most objective data for your doctor.

  • Lymphocyte Doubling Time (LDT): If your Absolute Lymphocyte Count (ALC) doubles in less than 6 months, it suggests the disease is moving more aggressively [9][10]. Caveat: This is generally only considered a trigger if your starting lymphocyte count is already quite high (typically over 30,000/μL). If your count goes from 5,000 to 10,000, that doubling is not an immediate cause for panic.
  • Marrow Failure: This is one of the most important triggers. It means the CLL cells are crowding out healthy cells in your bone marrow [5].
    • Anemia: A hemoglobin level below 10 g/dL [5][11].
    • Thrombocytopenia: A platelet count below 100,000/μL [5][11].

Remember, a rising white blood cell count alone is often not a reason to start treatment if you feel well and your other blood counts (red cells and platelets) are healthy [1][2]. The goal of Watch and Wait is to give you as many years as possible without the side effects of treatment, starting only when your body truly needs the help [1].

Common questions in this guide

What does active monitoring look like for CLL?
Active monitoring, or watch and wait, typically involves regular physical exams and blood work every 3 to 6 months. Your doctor tracks changes in how you feel and monitors your blood counts to ensure the disease remains stable.
What are the B symptoms of CLL?
B symptoms are physical signs that the leukemia is affecting your body's metabolism. These include unexplained weight loss, drenching night sweats, severe fatigue that prevents daily activities, and persistent fevers.
Should I start treatment if my white blood cell count goes up?
A rising white blood cell count alone is often not enough to trigger treatment. If you feel well and your red blood cells and platelets are healthy, your doctor will likely continue active monitoring to delay treatment side effects.
What is Lymphocyte Doubling Time (LDT)?
LDT measures how quickly your Absolute Lymphocyte Count doubles. If it doubles in less than six months and your starting count is high, it can suggest the disease is moving more aggressively.
Why is a fever dangerous during CLL watch and wait?
CLL compromises your immune system, making infections a major risk. Because of this, any fever over 100.4°F must be treated as a potential infection and reported to your medical team immediately rather than waiting to see if it resolves.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do you calculate my lymphocyte doubling time (LDT), and what is it based on my last three blood tests?
  2. 2.Are my current lymph node sizes considered 'massive' or 'progressive' under the iwCLL guidelines?
  3. 3.Since my hemoglobin and platelets are still in the normal range, does that confirm my bone marrow is still functioning well?
  4. 4.If I develop a fever or night sweats, how do we determine if it is from CLL or just a common infection?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    When and How Long to Treat Chronic Lymphocytic Leukemia?

    Niemann CU, Varghese A, Munir T, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e473656 doi:10.1200/EDBK-25-473656.

    PMID: 40273385
  2. 2

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

    Wierda WG, Byrd JC, Abramson JS, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(2)):185-217.

    PMID: 32023533
  3. 3

    Frequency of <em>TP53</em> Mutation in B-Cell Chronic Lymphocytic Leukaemia and its Association with Lymphocyte Doubling Time.

    Ali SM, Irfan SM, Raza N

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2023; (33(11)):1249-1253 doi:10.29271/jcpsp.2023.11.1249.

    PMID: 37926876
  4. 4

    Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

    Stilgenbauer S, Eichhorst B, Schetelig J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(19)):1973-1980 doi:10.1200/JCO.2017.76.6840.

    PMID: 29715056
  5. 5

    SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.

    Choi MY, Wang HY, Kipps TJ

    Clinical lymphoma, myeloma & leukemia 2019; (19(6)):321-325 doi:10.1016/j.clml.2019.05.013.

    PMID: 31204237
  6. 6

    "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel therapies.

    Vadasz B, Zak T, Aldinger J, et al.

    Virchows Archiv : an international journal of pathology 2025; (486(4)):739-750 doi:10.1007/s00428-024-03920-7.

    PMID: 39243299
  7. 7

    International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

    Kittai AS, Marchetti M, Al-Sawaf O, et al.

    Blood 2025; (146(3)):291-303 doi:10.1182/blood.2024028064.

    PMID: 40239121
  8. 8

    Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma; Small Cell Variant: A Real Diagnostic Challenge. Case Presentation and Review of Literature.

    Ibrahim F, Al Sabbagh A, Amer A, et al.

    The American journal of case reports 2020; (21()):e921131 doi:10.12659/AJCR.921131.

    PMID: 32150530
  9. 9

    Chronic lymphocytic leukaemia: from genetics to treatment.

    Bosch F, Dalla-Favera R

    Nature reviews. Clinical oncology 2019; (16(11)):684-701 doi:10.1038/s41571-019-0239-8.

    PMID: 31278397
  10. 10

    Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.

    Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al.

    Leukemia 2020; (34(8)):2038-2050 doi:10.1038/s41375-020-0747-7.

    PMID: 32071431
  11. 11

    Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.

    Wiedmeier-Nutor J, Leis J

    Current treatment options in oncology 2022; (23(6)):904-919 doi:10.1007/s11864-022-00953-5.

    PMID: 35435617

This page provides general information about CLL monitoring and symptoms for educational purposes. Always consult your hematologist or oncologist for medical advice and to evaluate your specific lab results and symptoms.

Get notified when new evidence is published on B-cell chronic lymphocytic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.